NCI is collaborating with Kaiser Permanente Northern California (KPNC) to create a carcinogenic human papillomavirus (HPV)-positive cohort for investigating the natural history of HPV genotypes. The carcinogenicity of the 15 HPV types with carcinogenic potential varies greatly, and investigators wish to increase the already proven clinical utility of carcinogenic HPV DNA testing in women 30 and older by understanding the unique properties of individual HPV types for viral persistence and progression. Investigators at the University of Montreal are testing specimens from the cohort to look at whether new HPV infections vary in risk of cervical intraepithelial neoplasia grade 2 or worse by age.